Long term natalizumab treatment in terms of no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis: A single center, real world retrospective cohort study
Latest Information Update: 21 Nov 2017
Price :
$35 *
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2017 New trial record
- 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis